Dashboard
Manage Tickers

KNSA


()    

CLICK TO SEE RELEVANT LITIGATION UPDATES
Y-mAbs Therapeutics, Inc. | YMAB | Take Action!
QQQ ()
DIA ()
SPY ()
TLT ()
GLD ()
$ na
-- x --
-- x --
-- - --
-- - --
--
na
--
--
--
TBD
--
-- (--)
--
TBD --
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
No Data found
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

jefferies-initiates-coverage-on-kiniksa-pharmaceuticals-with-buy-rating-announces-price-target-of-40
Jefferies Initiates Coverage On Kiniksa Ph...
09/13/2024 13:04:53

Jefferies analyst Roger Song initiates coverage on Kiniksa Pharmaceuticals (NASDAQ:KNSA) with a Buy rating and announces Pri...

why-comcast-shares-are-trading-lower-by-6-here-are-other-stocks-moving-in-tuesdays-mid-day-session
Why Comcast Shares Are Trading Lower By 6%...
07/23/2024 17:21:51

wedbush-maintains-outperform-on-kiniksa-pharmaceuticals-raises-price-target-to-34
Wedbush Maintains Outperform on Kiniksa Ph...
07/23/2024 16:55:07

Wedbush analyst David Nierengarten maintains Kiniksa Pharmaceuticals (NASDAQ:KNSA) with a Outperform and raises the price ta...

danaher-posts-upbeat-earnings-joins-spotify-msci-owens--minor-and-other-big-stocks-moving-higher-on-tuesday
Danaher Posts Upbeat Earnings, Joins Spoti...
07/23/2024 15:04:22

kiniksa-expects-2024-arcalyst-net-product-revenue-of-405m-415m-compared-to-prior-guidance-of-between-370m-390m-the-company-expects-to-remain-cash-flow-positive-on-an-annual-basis
Kiniksa Expects 2024 Arcalyst Net Product ...
07/23/2024 11:35:56

kiniksa-pharmaceuticals-q2-2024-gaap-eps-006-inline-sales-108631m-beat-92313m-estimate
Kiniksa Pharmaceuticals Q2 2024 GAAP EPS $...
07/23/2024 11:31:45

kiniksa-pharmaceuticals-commences-enrollment-in-its-abiprubart-phase-2b-clinical-trial-in-sjgrens-disease
Kiniksa Pharmaceuticals Commences Enrollme...
07/09/2024 12:04:18

kiniksa-pharmaceuticals-sponsors-american-heart-associations-addressing-recurrent-pericarditis-initiative--to-improve-quality-of-care-through-identification-dissemination-and-implementation-of-best-practices-for-the-diagnosis-and-management-of-recurrent-pericarditis
Kiniksa Pharmaceuticals Sponsors American ...
06/17/2024 12:37:01

– Initiative aimed at improving access and outcomes for patients with recurrent pericarditis – – American Heart Association to ...

kiniksa-pharmaceuticals---expects-redomiciliation-to-take-effect-on-or-around-june-27-2024--supreme-court-of-bermuda-issued-an-order-sanctioning-scheme-of-arrangement-between-company-and-its-shareholders
Kiniksa Pharmaceuticals - Expects Redomici...
06/14/2024 20:32:15

-SEC Filing

wells-fargo-initiates-coverage-on-kiniksa-pharmaceuticals-with-overweight-rating-announces-price-target-of-34
Wells Fargo Initiates Coverage On Kiniksa ...
05/03/2024 15:48:59

Wells Fargo analyst Eva Fortea Verdejo initiates coverage on Kiniksa Pharmaceuticals (NASDAQ:KNSA) with a Overweight rating ...

jp-morgan-maintains-overweight-on-kiniksa-pharmaceuticals-raises-price-target-to-30
JP Morgan Maintains Overweight on Kiniksa ...
05/01/2024 14:47:44

JP Morgan analyst Anupam Rama maintains Kiniksa Pharmaceuticals (NASDAQ:KNSA) with a Overweight and raises the price target ...

evercore-isi-group-maintains-outperform-on-kiniksa-pharmaceuticals-raises-price-target-to-30
Evercore ISI Group Maintains Outperform on...
04/24/2024 17:39:50

Evercore ISI Group analyst Liisa Bayko maintains Kiniksa Pharmaceuticals (NASDAQ:KNSA) with a Outperform and raises the pric...

kiniksa-expects-2024-arcalyst-net-product-revenue-of-370m-390m-compared-to-prior-guidance-of-360m-380m
Kiniksa Expects 2024 Arcalyst Net Product ...
04/23/2024 11:33:50

kiniksa-pharmaceuticals-q1-2024-gaap-eps-025-misses-014-estimate-sales-79858m-beat-78460m-estimate
Kiniksa Pharmaceuticals Q1 2024 GAAP EPS $...
04/23/2024 11:32:43

Kiniksa Pharmaceuticals (NASDAQ:KNSA) reported quarterly losses of $(0.25) per share which missed the analyst consensus estimat...

earnings-scheduled-for-april-23-2024
Earnings Scheduled For April 23, 2024
04/23/2024 10:56:59

Companies Reporting Before The Bell • RTX (NYSE:RTX) is expected to report quarterly earnings at $1.23 per share on revenue of...

kiniksa-expects-2024-arcalyst-net-product-revenue-of-between-360m-380m-that-its-cash-cash-equivalents-and-short-term-investments-will-fund-its-current-operating-plan-into-at-least-2027
Kiniksa Expects 2024 ARCALYST Net Product ...
02/28/2024 12:31:51

Financial GuidanceKiniksa expects 2024 ARCALYST net product revenue of between $360 million and $380 million.Kiniksa expects th...

kiniksa-pharmaceuticals-q4-eps-035-beats-014-estimate-sales-8339m-beat-7202m-estimate
Kiniksa Pharmaceuticals Q4 EPS $0.35 Beats...
02/28/2024 12:31:01

Kiniksa Pharmaceuticals (NASDAQ:KNSA) reported quarterly earnings of $0.35 per share which beat the analyst consensus estimate ...

earnings-scheduled-for-february-28-2024
Earnings Scheduled For February 28, 2024
02/28/2024 11:24:02

Companies Reporting Before The Bell • ICL Group (NYSE:ICL) is likely to report quarterly earnings at $0.08 per share on revenu...

earnings-outlook-for-kiniksa-pharmaceuticals
Earnings Outlook For Kiniksa Pharmaceuticals
02/27/2024 18:00:56

kiniksa-pharmaceuticals-says-arcalyst-rilonacept-2023-net-product-revenue-grew-90-yoy-to-2331m-sees-arcalyst-2024-net-product-revenue-of-360m-380m
Kiniksa Pharmaceuticals Says ARCALYST (ril...
01/04/2024 12:48:09

CORE & Plaid

CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION